1228570-47-5

Basic information

• Product Name: (2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID
• Synonyms: (2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID;Boc-(R)-2-amino-2-(4-bromophenyl)acetic acid;(R)-2-(4-Bromophenyl)-2-((tert-butoxycarbonyl)amino)acetic acid;N-Boc-R-4-Bromophenylglycine
• CAS NO: 1228570-47-5
• Molecular Formula: C13H16BrNO4
• Molecular Weight: 330.17444
• EINECS: -0
• Mol File: 1228570-47-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 465.1±40.0 °C(Predicted)
• Appearance: /
• Density: 1.443±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.38±0.10(Predicted)
• CAS DataBase Reference: (2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID(1228570-47-5)
• EPA Substance Registry System: (2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID(1228570-47-5)

Safety Data

• Hazardous Substances Data: 1228570-47-5(Hazardous Substances Data)

Usage

General Description

(2R)-2-[(tert-butoxy)carbonylamino]-2-(4-bromophenyl)acetic acid is a chemical compound with the molecular formula C15H20BrNO4. It is a chiral compound with a 2R stereochemistry. (2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID contains a tert-butoxy carbonyl group, an amino group, and a bromophenyl group, as well as a carboxylic acid functional group. It is commonly used as a reagent in organic synthesis and medicinal chemistry, particularly in the development of pharmaceutical drugs. Its specific chemical properties and potential biological activities make it a valuable tool in the field of drug discovery.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 71079-03-3 (R)-4-bromophenylglycine 
• 848188-26-1 (S)-Amino-(4-bromo-phenyl)-acetic acid 
• 119397-06-7 2-amino-2-(4-bromophenyl)acetic acid 

Downstream Products

• 917925-68-9 [(4-bromo-phenyl)-(5-phenyl-1H-imidazol-2-yl)-methyl]-carbamic acid tert-butyl ester 
• 369403-44-1 2-([1,1'-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)acetic acid 

Relevant articles and documents

Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines

The serine protease, PACE4, is a proprotein convertase that plays a substantial role in malignancy of prostate cancer. Our initial selective PACE4 inhibitor (Ac-LLLLRVKR-NH2) has evolved to the current lead compound C23 (Ac-dLeu-LLLRVK-Amba), w

BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Dihydropyridine compound and application thereof to drugs

The invention relates to a dihydropyridine compound and application of the dihydropyridine compound serving as a drug, in particular to application of the dihydropyridine compound serving as a drug for treating and preventing hepatitis B. Specifically, the invention relates to the compound shown as the general formula (I) or (Ia) (please see the specifications for the general formula (I) or (Ia))or stereoisomers, tautomer, a nitrogen oxide, solvate, metabolites and medically acceptable salt of the compound or a prodrug of the compound, wherein all variables are defined in the specification. The invention further relates to application of the compound shown as the general formula (I) or (Ia) or enantiomers, non-enantiomers, the tautomer, hydrates, the solvate or the medically acceptable salt of the compound serving as drugs, in particular to application of the compound or the enantiomers, the non-enantiomers, the tautomer, the hydrates, the solvate or the medically acceptable salt of the compound serving as the drugs for treating and preventing hepatitis B.